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http:WHAT THIS PAPER ADDS
Polidocanol endovenous microfoam (PEM) is a proprietary treatment for the symptoms and appearance of
varicose veins in patients with saphenofemoral junction (SFJ) incompetence. PEM is intended to treat all
incompetent veins of the great saphenous vein (GSV) system, including the proximal and distal GSV and
associated trunk veins, tortuous veins, and/or visible varicosities.Objective: This multicenter, parallel group study was designed to determine if a single administration of 15 mL
of pharmaceutical-grade polidocanol endovenous microfoam (PEM, now approved in the United States as
Varithena [polidocanol injectable foam], BTG International Ltd.) could alleviate symptoms and improve
appearance of varicose veins in a typical population of patients with moderate to very severe symptoms of
superﬁcial venous incompetence and visible varicosities of the great saphenous vein (GSV) system.
Methods: The primary endpoint was patient-reported venous symptom improvement measured by change from
baseline toWeek 8 in 7-day average VVSymQ score. Co-secondary endpointsmeasured improvement in appearance
of visible varicose veins from baseline to Week 8, as measured by the Independent Photography RevieweVisible
Varicose Veins (IPR-V3) and Patient Self-assessment of Visible Varicose Veins (PA-V3) scores. Patients were
randomized to ﬁve groups: PEM 0.125% (control), 0.5%, 1%, 2%, or placebo. Adverse events (AEs) were recorded at
each study visit.Tertiary endpoints measured duplex ultrasound response, changes in venous clinical severity score,
and the modiﬁed Venous Insufﬁciency Epidemiological and Economic StudyeQuality of Life/Symptoms.
Results: At Week 8, VVSymQ scores for the pooled PEM group (0.5% þ 1% þ 2%; p < .0001) and individual dose
concentrations (p < .001) were signiﬁcantly superior to placebo. Mean changes from baseline to Week 8 in IPR-
V3 and PA-V3 scores were signiﬁcantly greater for pooled PEM than for placebo (p < .0001). Most AEs were mild
and resolved without sequelae. No pulmonary emboli were reported.
Conclusions: This study demonstrated that a single administration of up to 15 mL of PEM is a safe, effective, and
convenient treatment for the symptoms of superﬁcial venous incompetence and the appearance of visible
varicosities of the GSV system. Doses of 0.5%, 1%, and 2% PEM appear to have an acceptable risk-beneﬁt ratio.
 2015 The Authors. Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1. Questions, responses, and method of scoring in the
VVSymQ questionnaire.
“Since waking up today, how often have you had
the following problem in your leg to be treated?”
This question was asked for each of the following
ﬁve symptoms: heaviness, achiness, swelling,
throbbing, and itching.
Response to question:
Scoring
“None of the time” 0
“A little of the time” 1
“Some of the time” 2
“A good bit of the time” 3
“Most of the time” 4
“All of the time” 5
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Varicose veins of the lower limbs affect between 25% and
35% of adults in the Western world. In more than 80% of
cases the cause is saphenous vein incompetence.1,2 Some
people are asymptomatic, but many experience heaviness,
achiness, swelling, throbbing and/or pain, and itching,
which can negatively affect their health-related quality of
life.2,3
A number of vein disease-speciﬁc quality of life in-
struments are available to assess the impact of varicose
veins, but these do not measure patient-reported symp-
toms. The VVSymQ Instrument (BTG International, Inc.,
London, UK) was speciﬁcally designed to measure symp-
toms of superﬁcial venous incompetence and detect clini-
cally meaningful changes in patients’ symptoms following
intervention.4 This instrument was developed following the
United States Food and Drug Administration (FDA) guide-
lines for establishing a ‘ﬁt for purpose’ patient-reported
outcomes instrument to support the indication of a medi-
cal product.5 The nature of questions and measurement
scales used were based on several iterations of formal pa-
tient interviews. The instrument’s performance attributes
were validated in a separate clinical study.6 The resultant
VVSymQ Instrument assesses ﬁve symptoms of varicose
veins: Heaviness, Achiness, Swelling, Throbbing, and Itching
(HASTI), deﬁned by patients as being their most important
symptoms. The VVSymQ Instrument assesses these symp-
toms on a daily duration-based scale recorded by patients
via an electronic daily diary.
Polidocanol endovenous microfoam (PEM) is a ﬂexible
treatment for varicose veins, the incompetent great
saphenous vein (GSV), major saphenous accessory veins,
and visible varicosities of the GSV system above and below
the knee improving symptoms and appearance. This
pharmaceutical grade, low-density sterile PEM is gener-
ated from a proprietary canister system. The gas mixture
used to generate PEM is a precise mixture of oxygen and
carbon dioxide (65:35), with low nitrogen content
(<0.8%). It has a deﬁned density, bubble size distribution,
and half separation time (i.e. stability), with median
bubble diameter of approximately 100 mm and no bubbles
>500 mm, enabling efﬁcient delivery of sclerosant to the
venous endothelium. Each mL of PEM contains 1.3 mg of
polidocanol.
PEM has been studied in more than 1300 patients. The
ﬁrst of two pivotal trials demonstrated that the 0.5% and
1.0% doses were effective and provided clinically mean-
ingful beneﬁt in treating the symptoms and appearance of
varicose veins.7 Here, the results of the second pivotal trial
are presented.METHODS
Patients
Male and female patients aged 18e75 years who had
saphenofemoral junction (SFJ) incompetence, reﬂux (>0.5
seconds on duplex ultrasonography) of the GSV or othermajor accessory saphenous veins determined by duplex
ultrasound, and both symptoms and visible varicosities
were enrolled. The GSV diameter (mm) was measured
5 cm below the SFJ. Patients needed to be able to com-
plete the VVSymQ electronic diary and have visible disease
that was moderate, severe, or very severe, including leg
ulcer C6. Exclusion criteria included: small saphenous and
deep vein incompetence, history of or active deep vein
thrombosis (DVT), pulmonary embolism (PE), or stroke;
inability to comply with post-treatment compression or
walk unaided. There were no exclusions for medications,
including anticoagulants. Importantly, there were no re-
strictions on vein diameter or tortuosity of veins to be
treated.
Study design
This study evaluated the efﬁcacy and safety of PEM (0.5%,
1%, and 2%) compared with 0.125% (control) and placebo.
Here, reports are made on all patients through the primary
efﬁcacy endpoint at Week 8. Patients continued to be fol-
lowed for 1 year. After completion of all assessments for the
primary endpoint at Week 8, patients could receive open-
label treatment with 1% PEM.
Primary endpoint
The primary endpoint was change from baseline to Week 8
in the 7-day average VVSymQ score. Data were collected
using an electronic diary (invivodata, Inc. [now ERT], Pitts-
burgh, PA, USA). Patients completed evening reports on
each of the 10 days preceding the treatment day (baseline),
Week 4, and Week 8 visits, and data were automatically
transferred to a secure server. Patients recorded duration
and intensity of nine symptoms and activity levels during
the previous 24 hours; in total they answered 20 questions,
ﬁve of which contributed to the VVSymQ score. The
VVSymQ score is the sum of the ﬁve HASTI symptoms
scores on a 0e5 duration scale (0 ¼ none of the time to
5 ¼ all of the time) giving a daily symptom score of 0 to 25
(Table 1). A daily average was calculated for the 7 most
recent days prior to each study visit (or a minimum of 4
days if there was a missing report) to calculate an average
VVSymQ score.
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Appearance: Co-secondary efﬁcacy endpoints measured
improvement in the appearance of visible varicose veins
from baseline to Week 8, as measured by the Independent
Photography RevieweVisible Varicose Veins (IPR-V3) and
Patient Self-assessment of Visible Varicose Veins (PA-V3)
scores.8 The IPR-V3 score was the median rating of an
expert panel of three clinicians who assessed the severity of
appearance of each patient’s visible varicose veins by
reviewing standardized digital photographs. The IPR-V3 used
a 5-point scale ranging from 0 to 4 (none, mild, moderate,
severe, or very severe). Standardized digital photography
was developed in conjunction with Canﬁeld Scientiﬁc Inc.
(Fairﬁeld, NJ, USA), including controlled illumination to aid
in capturing surface contours. Each reviewer independently
scored each leg photograph using a high-resolution monitor
and specialized software that allowed the reviewer to zoom
and pan thus approximating a live review. The images were
presented, in random order to each reviewer, one at a time.
The reviewer was blinded to patient, time point, and
treatment assignment.
The PA-V3 score was the patient’s self-assessment of
their varicose veins. Similar to the IPR-V3, the PA-V3 used a
5-point noticeability scale and each patient was instructed
to choose one of ﬁve statements that best described the
actual appearance of visible varicose veins of the study leg
at baseline, Week 4, and Week 8: not at all noticeable (0),
slightly noticeable (1), moderately noticeable (2), very
noticeable (3), or extremely noticeable (4).
Clinically meaningful change: Patients completed sepa-
rate global impression of change questionnaires to deter-
mine if changes in symptoms and appearance at Weeks 4
and 8 were clinically meaningful. The patient global
impression of change questionnaires used a 7-point scale
(similar to a Likert scale) to report overall patient beneﬁt (or
decline) following treatment. Clinically meaningful change
was deﬁned as the percent of patients whose symptoms or
appearance had “moderately improved” or “much
improved,” which were the two highest scores on the 7-
point scale.
Tertiary endpoints
(1) Duplex ultrasound deﬁned as: the elimination of SFJ
reﬂux and/or complete occlusion of the target vein(s), that
is incompetent GSV and/or major saphenous accessory
vein; (2) change in the revised venous clinical severity score
(VCSS)9; and (3) change in the modiﬁed VEINES-QOL/Sym
(Venous Insufﬁciency Epidemiological and Economic
StudyeQuality of Life/Symptoms) score for the previous
week’s recall.10,11 All tertiary endpoints were assessed at
Week 8.
Ethics
This study complied with the International Conference on
Harmonisation Good Clinical Practice and the Declaration
of Helsinki (1996).12 The protocol and all associated ma-
terials were approved by Schulman Associates IRB or localIRBs. Registered on http://clinicaltrials.gov/show/
NCT01072877.13
Randomization
Patients were equally randomized to PEM 0.125% (control),
0.5%, 1%, 2%, or placebo. Randomization was stratiﬁed by
baseline symptom score and site using an automated
interactive voice recognition system (IVRS, United States,
Biosource Corporation, San Francisco, CA, USA).
Treatment
All patients underwent blinded treatment session, a
maximum volume of 15 mL of study drug (in 5 mL aliquots)
was allowed regardless of treatment assignment. All PEM
dose concentrations were in identical canisters identiﬁed
only by an individual numeric code assigned by the IVRS.
Placebo (agitated diluent solution, 5 mL aliquots) was pre-
pared immediately prior to injection. The vein(s) to be
treated was cannulated at the mid-thigh under ultrasound
guidance. Up to 5 mL of study drug was injected proximally
under ultrasound guidance from the site of the cannulation
to a point 5 cm distal to the SFJ. Additional study drug was
injected distally to ﬁll both the GSV from the mid-thigh
catheter and visible varicose tributaries. The treated leg
was wrapped in a short-stretch bandage with compression
pads that provided eccentric pressure over the treated
venous segments. An overstocking and thigh-length 30e
40 mmHg compression stocking with waist band (Venosan
North America, Asheboro, NC, USA) were placed over the
dressing. The compression bandages and stocking were
worn continuously for 48 hours. The compression stocking
alone was worn continuously for an additional 12 days.
Patients were mobilized when treatment was complete and
were encouraged to walk for at least 5 minutes during each
waking hour for the week following treatment.
Safety
Documentation of adverse events (AEs), regardless of
severity or causality, began after the patient had signed the
informed consent and continued until the patient had
completed Visit 5/Week 8 (or Visit 8 for patients who
received optional, open-label 1% PEM following Visit 5). At
each study visit after the initial treatment, AEs, concomitant
medications, and procedures were recorded.
Duplex ultrasound surveillance
One week after study treatment (initial or optional treat-
ment), patients had a follow-up visit to evaluate for safety
using detailed per-protocol duplex ultrasound assessments
of the deep veins. This involved repeated compression and
color ﬂow at regular intervals from the medial malleolus
upward. If a thrombus AE was identiﬁed, patients under-
went additional duplex scans 1 and 2 weeks later, and then
monthly until any thrombi stabilized or resolved. Patients
were evaluated for symptoms of venous thromboembolic
events. Management of thrombi was according to clinical
Figure 1. A total of 785 patients were screened. Five-hundred and one patients (64%) failed screening. Two-hundred and eighty-four (284)
patients were randomized. During the blinded phase of the study (through Visit 5/Week 8), patients received PEM 0.125%, 0.5%, 1.0%, 2.0%
or Vehicle placebo at Visit 2. Following the Week 8 visit (Visit 5), patients could receive open-label treatment with PEM 1.0% at Visit 6.
Treatment of Truncal Incompetence and Varicose Veins 787presentation and usual clinical practice. Recommendations
consistent with the American College of Chest Physicians
guidelines were provided for anticoagulation.14 All venous
thrombotic events were reviewed by the sponsor and an
independent safety review board, which met at least every
6 months during the trial.Blinding
It was not possible to create placebo foam that is indistin-
guishable from PEM; thus physician and ultrasonographer
were unblinded to placebo. The PEM 0.125% arm was
added, 0.125% being the lowest concentration of polido-
canol that can generate foam, which was presumed to be
sub-therapeutic, to allow blinded evaluation of duplex
response results. Placebo solution contained the excipients
of PEM, and was visible on ultrasound when agitated using
the Tessari method after administration.15 Importantly, as-
sessors for all primary and secondary endpoints were
completely blinded. Drapes or screening were used toobscure the patient’s view of the treatment procedure. An
evaluation of patient blinding to treatment assignment was
obtained after the initial blinded study treatment session,
and at Weeks 4 and 8.Statistical analysis
The primary endpoint was absolute change from baseline in
VVSymQ score at Week 8. Sample size was selected to
provide 95% power to detect an absolute mean difference
between pooled PEM (0.5%, 1%, and 2%) and placebo.
Forty-ﬁve patients per treatment group with at least one
VVSymQ score by Week 8 were required, assuming a SD of
4.75, using a two-sample t test and two-sided a ¼ 0.05.
Under these same assumptions, demonstration of statistical
superiority between individual concentration and placebo
would have 84% power. The study was not powered to
demonstrate differences between PEM concentrations.
Data management and statistical analysis were conducted
by United BioSource Corporation (Blue Bell, PA, US).
Table 2. Patient demographics.
Placebo
n ¼ 56
PEM 0.125%
n ¼ 57
PEM 0.5%
n ¼ 51
PEM 1%
n ¼ 52
PEM 2%
n ¼ 63
All patients
N ¼ 279
Age, years
Mean (SD)
46.0
(11.31)
51.6
(9.60)
48.2
(11.78)
48.8
(8.78)
49.7
(10.49)
48.9
(10.54)
Sex, female, n (%) 44 (78.6) 42 (73.7) 37 (72.5) 38 (73.1) 47 (74.6) 208 (74.6)
Race, white 52 (92.9) 51 (89.5) 46 (90.2) 50 (96.2) 61 (96.8) 260 (93.2)
BMI (kg/m2)
Mean (SD)
27.7
(5.95)
28.8
(5.77)
27.4
(5.75)
28.6
(5.41)
28.3
(5.40)
28.2
(5.64)
GSV diameter (mm)
Mean
7.70
(n ¼ 50)
7.26
(n ¼ 52)
7.59
(n ¼ 45)
7.91
(n ¼ 48)
7.68
(n ¼ 61)
7.63
(n ¼ 256)
C class, n (%)
C2 22 (39.3) 32 (56.1) 25 (49.0) 26 (50) 32 (50.8) 137 (49.1)
C3 24 (42.9) 14 (24.6) 13 (25.5) 15 (28.8) 13 (20.6) 79 (28.3)
C4 10 (17.9) 11 (19.3) 10 (19.6) 9 (17.3) 17 (27.0) 57 (20.4)
C5 and C6 0 0 3 (5.9) 2 (3.8) 1 (1.6) 6 (2.2)
Table 3. Improvement in symptoms of varicose veins as measured by VVSymQ at Week 8.
VVSymQ
Placebo PEM
0.125%
PEM
0.5%
PEM
1%
PEM
2%
PEM
(0.5%, 1%, 2%)
Baseline score, mean 8.60
(n¼55)
9.01
(n ¼ 56)
9.30
(n ¼ 51)
8.82
(n ¼ 50)
9.49
(n ¼ 63)
9.23
(n ¼ 164)
Adjusted mean change from baseline: Week 8 ̶2.13
(n¼55)
̶4.63
(n ¼ 56)
̶5.68
(n ¼ 51)
̶4.87
(n ¼ 50)
̶5.78
(n ¼ 63)
̶5.44
(n ¼ 164)
Clinically meaningful improvement in symptoms:
Week 8
6%
(n¼53)
44%
(n ¼ 50)
81%
(n ¼ 47)
63%
(n ¼ 46)
81%
(n ¼ 59)
7%
(n ¼ 152)
Comparison vs. placebo: Week 8, p value,
adjusted mean change
<.0001 <.0001 <.0001 <.0001 <.0001
For VVSymQ, lower scores and/or negative change scores indicate better outcomes.
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Patients
Seven-hundred and eighty-ﬁve patients were screened at 19
US study sites; 284 were randomized and 279 were treated
with either placebo (n ¼ 56) or PEM 0.125% (n ¼ 57), 0.5%
(n ¼ 51), 1% (n ¼ 52), or 2% (n ¼ 63). Two-hundred and
seventy-ﬁve patients completed the study to Week 8. Fig. 1
depicts patient disposition for this study.Figure 2. At Week 8, for patients in the PEM 0.5%, 1.0%, and 2.0%
treatment groups, the mean VVSymQ score had decreased by
approximately 60% of the baseline mean value compared with a
decline of approximately 20% in the Vehicle group. No signiﬁcant
difference was seen across the three dose concentrations.Demographics
Baseline characteristics were similar across treatment
groups (Table 2). Most patients were Caucasian women,
with a mean age of 49 years and mean BMI of 28 kg/m2.
Approximately 98% of patients had venous disease (C2-C4).
Mean GSV diameter at baseline was 7.63 mm (range 1.5e
25.9 mm).Treatments
Of the 284 patients randomized, ﬁve withdrew before
treatment. For patients receiving PEM at Visit 2, median total
volume administered was 13.0 mL in the 0.125% group and
12.0 mL in the 0.5%, 1%, and 2% groups. At Visit 6, patients
could receive optional treatment with open-label 1% PEM;
93% of placebo patients, 74% of 0.125% patients, 63% of
0.5% patients, 56% of 1% patients, and 51% of 2% patients
received open-label treatment. For 96% of placebo patients,
the reason for open-label treatment was treatment failure
compared with 60% of 0.125% patients, 55% of 0.5% pa-
tients, 34% of 1.0% patients, and 39% of 2.0% patients.Primary outcome measure: relief of symptoms
At Week 8, VVSymQ scores for pooled PEM
(0.5% þ 1% þ 2%) patients were signiﬁcantly superior to
placebo (p < .0001). VVSymQ scores decreased signiﬁcantly
(p < .0001) from baseline to Week 8 for all PEM individual
doses (Table 3 and Fig. 2).
Table 4. Improvement in appearance of varicose veins as measured by IPR-V3 and PA-V3 at Week 8.
Placebo PEM
0.125%
PEM
0.5%
PEM
1%
PEM
2%
Pooled PEM
(0.5%, 1%, 2%)
IPR-V3
Baseline score,a mean (nb) 1.82 (n ¼ 55) 1.95 (n ¼ 56) 2.12 (n ¼ 51) 1.98 (n ¼ 49) 2.10 (n ¼ 61) 2.07 (n ¼ 161)
Adjusted meanc change from
baseline: Week 8
̶0.01 ̶0.46 ̶0.77 ̶0.76 ̶0.91 ̶0.81
Comparison vs. placebo:
Week 8, p valued
0.0001 <0.0001 <0.0001 <0.0001 <0.0001
PA-V3
Baseline score,a mean (nb) 3.49 (n ¼ 55) 3.57 (n ¼ 56) 3.45 (n ¼ 51) 3.46 (n ¼ 50) 3.68 (n ¼ 63) 3.54 (n ¼ 164)
Adjusted meanc change from
baseline: Week 8
̶0.15 ̶0.93 ̶1.40 ̶1.60 ̶1.75 ̶1.58
Comparison vs. placebo:
Week 8, p valued
.0001 <.0001 <.0001 <.0001 <.0001
a Visit 2 (baseline).
b Number of patients with both a baseline value and a value at the corresponding visit.
c Least square means from analysis of covariance (ANCOVA) model with treatment group and site as class variables and corresponding
baseline score from the questionnaire as a continuous covariate.
d Two-sided signiﬁcance level for paired comparisons.
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Mean changes from baseline to Week 8 in IPR-V3 and PA-V3
scores were signiﬁcantly greater in the pooled PEM group
compared with the placebo group (p < .0001; Table 4). All
therapeutic PEM dose concentrations were signiﬁcantly
superior to placebo (p  .0001) in reduction of IPR-V3 and
PA-V3 scores at Week 8.Tertiary outcome measures: measured response
Tertiary endpoints measured response to treatment at
Week 8 by duplex ultrasound, VCSS, and VEINES-QOL/Sym.Table 5. Response to treatment as measured by duplex ultrasound, rV
Duplex response
Placebo
na ¼ 56
PEM
0.1
n ¼
Responders, n (%) 3 (5.4) 24
Comparison of 0.125% vs. pooled PEM: Week 8,
p valueb
Revised VCSS
Placebo
n ¼ 55
PE
0.1
n
Baseline score,c mean 7.11 7.4
Adjusted meand change from baseline: Week 8 ̶0.75 ̶2
Comparison vs. placebo: Week 8, p valueb <.
VEINES-QOL
Placebo
n ¼ 55
PEM
0.12
n ¼
Baseline score,c mean 53.12 53.6
Adjusted meand change from baseline: Week 8 7.67 16.2
Comparison vs. placebo: Week 8, p valueb 0.00
a Number of patients with a baseline value and a value at the corresp
b Two-sided signiﬁcance level for paired comparisons.
c Visit 2 (baseline).
d Least square means from ANCOVA model with treatment group and s
questionnaire as a continuous covariate.Duplex ultrasound response rates for patients treated with
PEM 0.5%, 1%, 2% foam (pooled and individually) ranged
from 59% to 83%, and were signiﬁcantly superior to those
in patients treated with PEM 0.125% foam (42%, p < .0001;
Table 5). Additionally, a statistically signiﬁcant trend be-
tween response and PEM concentration was evident
(p < .001) (Fig. 3). A formal dose response analysis was
conducted and non-zero correlation (linear trend) was
p < .0001. For pooled PEM and individual PEM dose con-
centrations, improvements in revised VCSS and VEINES-
QOL/Sym scores at Week 8 were statistically superior to
changes observed in the placebo group (p  .0001 in all
CSS, and VEINES-QOL/Sym at Week 8.
25%
57
PEM
0.5%
n ¼ 51
PEM
1%
n ¼ 51
PEM
2%
n ¼ 63
Pooled PEM
(0.5%, 1%, 2%)
n ¼ 165
(42.1) 30 (58.8) 41 (80.4) 52 (82.5) 123 (74.5)
.0539 <.0001 <.0001 <.0001
M
25%
¼ 55
PEM
0.5%
n ¼ 51
PEM
1%
n ¼ 49
PEM
2%
n ¼ 63
Pooled PEM
(0.5%, 1%, 2%)
n ¼ 163
0 7.18 7.39 7.13 7.22
.97 ̶3.79 ̶3.70 ̶4.39 ̶3.96
0001 <.0001 <.0001 <.0001 <.0001
5%
54
PEM
0.5%
n ¼ 51
PEM
1%
n ¼ 50
PEM
2%
n ¼ 62
Pooled PEM
(0.5%, 1%, 2%)
n ¼ 163
5 53.15 54.86 51.51 53.05
8 20.44 19.25 23.79 21.16
01 <0.0001 <0.0001 <0.0001 <0.0001
onding visit.
ite as class variables and the corresponding baseline score from the
Figure 3. A statistically signiﬁcant trend between response and polidocanol microfoam concentration was evident; 42.1% of the PEM
0.125% treatment group, 58.8% of the PEM 0.5% treatment group, 80.4% of the PEM 1.0% treatment group, and 82.5% of the PEM 2.0%
treatment group were responders to treatment (p < .0001).
790 J.T. King et al.cases). Mean changes in revised VCSS and VEINES-QOL/Sym
scores at Week 8 for patients in the pooled PEM group were
also statistically superior to changes observed in the PEM
0.125% group (p ¼ .0038 and p ¼ .0073, respectively).
Safety
There were no serious AEs and no PEs. Most AEs were mild,
resolved without sequelae, and were assessed by theTable 6. Treatment-emergent adverse events in 3% of patients, safe
Treatment group, n (%)
Blinded treatment
Adverse reaction Placebo
(n ¼ 56)
PEM
0.125%
(n ¼ 57)
PEM
0.5%
(n ¼ 51
Pain in extremity 5 (8.9) 11 (19.3) 10 (19.6
Thrombophlebitis,
superﬁcial
1 (1.8) 17 (12.3) 5 (9.8)
Injection site hematoma 1 (1.8) 3 (5.3) 8 (15.7)
Limb discomfort 2 (3.6) 2 (3.5) 3 (5.9)
Venous thrombosis, limb 0 1 (1.8) 3 (5.9)
Injection site pain 2 (3.6) 3 (5.3) 4 (7.8)
Infusion site thrombosis 0 0 3 (5.9)
Pruritus 3 (5.4) 2 (3.5) 2 (3.9)
Headache 3 (5.4) 2 (3.5) 2 (3.9)
Peripheral edema 2 (3.6) 3 (5.3) 3 (5.9)
Upper respiratory tract
infection
0 3 (5.3) 2 (3.9)
Extravasation 1 (1.8) 1 (1.8) 1 (2.0)
Muscle spasms 1 (1.8) 1 (1.8) 2 (3.9)
Rash 2 (3.6) 2 (3.5) 0
Skin discoloration 1 (1.8) 2 (3.5) 1 (2.0)
Deep vein thrombosis 0 0 1 (2.0)
Nausea 0 2 (3.5) 0
Tenderness 1 (1.8) 0 0
Erythema 0 0 0
Visual impairment 0 0 2 (3.9)
Injection site discomfort 0 0 2 (3.9)
Contusion 0 0 0
Dizziness 0 0 2 (3.9)investigator as related to study treatment. In the blinded
phase of the study, patients treated with PEM 1% and 2%
foam had a lower rate of AEs than patients treated with
PEM 0.125% and 0.5% foam; however, patients receiving
higher PEM dose concentrations (1% and 2%) had higher
rates of severe AEs. The percent of patients with treatment-
emergent AEs was similar across PEM dose concentrations.
The most common AEs occurring in 3% of patients in anyty population.
Open label Total receiving
PEM
)
PEM
1.0%
(n ¼ 52)
PEM
2.0%
(n ¼ 63)
PEM
1.0%
(n ¼ 187) n ¼ 275
) 10 (19.2) 6 (9.5) 23 (12.3) 58 (21.1)
4 (7.7) 8 (12.7) 5 (2.7) 29 (10.5)
4 (7.7) 3 (4.8) 4 (2.1) 22 (8.0)
3 (5.8) 6 (9.5) 6 (3.2) 19 (6.9)
6 (11.5) 4 (6.3) 1 (0.5) 15 (5.5)
3 (5.8) 3 (4.8) 2 (1.6) 15 (5.5)
3 (5.8) 6 (9.5) 13 (7.0) 25 (9.1)
2 (3.8) 6 (9.5) 2 (1.1) 14 (5.1)
3 (5.8) 3 (4.8) 2 (1.1) 12 (4.4)
2 (3.8) 1 (1.6) 4 (2.1) 13 (4.7)
0 3 (4.8) 0 8 (2.9)
4 (7.7) 1 (1.6) 0 7 (2.5)
2 (3.8) 1 (1.6) 4 (2.1) 9 (3.3)
2 (3.8) 0 1 (0.5) 5 (1.8)
0 1 (1.6) 0 4 (1.5)
1 (1.9) 2 (3.2) 5 (2.7) 9 (3.3)
1 (1.9) 0 1 (0.5) 4 (1.5)
2 (3.8) 1 (1.6) 4 (2.1) 7 (2.5)
2 (3.8) 1 (1.6) 1 (0.5) 4 (1.5)
0 0 0 2 (0.7)
0 0 0 2 (0.7)
2 (3.8) 0 0 2 (0.7)
0 0 1 (0.5) 3 (1.1)
Treatment of Truncal Incompetence and Varicose Veins 791PEM treatment group are shown in Table 6. Treatment-
emergent AEs that occurred with the highest incidence in
the patients treated with PEM were superﬁcial thrombo-
phlebitis, pain in the extremity, and injection site hema-
toma. No patient discontinued the study because of an AE.
In the 174 PEM-treated patients with AEs, most were mild
or moderate (42% and 18%, respectively), but were severe
in 12 patients (4%). Approximately half of these AEs were
considered related to treatment and 91% resolved without
sequelae.
Venous thrombus AEs in a non-target vein occurred in 27
patients treated with PEM. Fifteen were classiﬁed as a
common femoral vein thrombus extension (analogous to
endovenous heat induced thrombosis [eHITs]16 described in
association with endovenous thermal ablation); ﬁve as
proximal DVT (popliteal vein or above); four as distal DVT;
and three as isolated gastrocnemius and soleal vein
thrombosis. No patients experienced a thrombus in more
than one location. One patient receiving PEM 2.0% reported
with common femoral vein thrombus extension and had
symptoms that could be considered consistent with a PE
(i.e., pleuritic chest pain and dyspnea) which resolved the
same day; a clinical diagnosis of PE was not made, and was
neither conﬁrmed nor excluded as the patient refused CT.
All thrombi were generally small and detected during the
protocol-required duplex ultrasound procedures; no patient
presented spontaneously with signs or symptoms of a
venous thrombus, despite speciﬁc inquiry. Most (88%)
thrombi were asymptomatic, and all resolved within 100
days (median time to stabilization or resolution: 21 days)
regardless of whether the patient was observed, or received
a short course (2 weeks) of low molecular weight heparin
or 3 months of anticoagulation.DISCUSSION
This was the second of two pivotal phase-3 clinical studies
designed to evaluate the efﬁcacy of a proprietary
pharmaceutical-grade PEM compared with placebo as part of
an FDA investigational new drug application. The efﬁcacy
results reported are at 8 weeks; longer-term results will
assess durability of beneﬁt at 1 year and out to 5 years. This
randomized, controlled study demonstrated the signiﬁcant
and clinically meaningful patient beneﬁt of treatment with
PEM in the improvement of symptoms and appearance of
varicose veins in patients with an incompetent GSV and/or
accessory saphenous veins and visible varicosities. Signiﬁcant
improvements in disease-speciﬁc quality of life and the clin-
ical severity of varicose veins also were demonstrated. This
conﬁrms the results of the VANISH-2 study,7 which showed
that PEM 0.5% and 1% foam provided clinically meaningful
beneﬁt for patients with a range of GSV diameters (1.5e
25.9 mm). There were no restrictions on inclusion criteria
related to vein diameter, vein tortuosity, or prior treatments
in either study. There was a low rate of deep venous thrombi,
no PEs, and no cerebrovascular or neurological events.
Instruments used to assess the efﬁcacy endpoints in this
study were speciﬁcally designed to evaluate the clinicalbeneﬁt of treatment in patients with superﬁcial venous
incompetence. Each of these instruments was developed in
accordance with an FDA guidance document.17 The content
validity of the VVSymQ and PA-V3 was established through
concept elicitation and cognitive debrieﬁng in patients with
superﬁcial venous incompetence. In contrast, many of the
instruments used in previous studies of venous disease,
such as the Speciﬁc Quality of Life Outcomes Responsee
Venous (SQOR-V) instrument18 and the VEINES-QOL/Sym
instrument,11 were developed without direct patient
input. The IPR-V3 was developed by expert clinicians who
treat patients with saphenous vein incompetence.
The current standard of care for the treatment of vari-
cose veins usually requires multiple procedures. Most
commonly, the proximal GSV is treated with endovenous
thermal ablation, and additional procedures of either
phlebectomy or sclerotherapy are necessary to provide a
complete treatment. In contrast, PEM can treat all veins
trunk vein or varicose tributaries.
Simple “closure” of the GSV, on duplex ultrasound, is
the usual efﬁcacy measure for endovenous thermal abla-
tion. However, GSV closure alone does not measure the
full hemodynamic effects of treatment, because accessory
saphenous veins might also be incompetent or can
become incompetent following GSV closure. As a result,
SFJ reﬂux and symptoms might not be eliminated. In this
study, a more comprehensive and challenging ultrasound
endpoint was used, requiring either occlusion of all
incompetent veins and or elimination of SFJ reﬂux. The
instruments used for the primary and secondary endpoints
in the present study assess what is most important to
patients.
Treatment with PEM is a minimally invasive, generally
safe, non-surgical procedure. Slightly more than half of all
study patients experienced at least one AE. In the 174 PEM-
treated patients with AEs, most were mild or moderate
(42% and 18%, respectively), and were severe in only 12
(4%) patients. Approximately half of these AEs were
considered related to treatment and most (91%) resolved
without sequelae. No PEs were reported. Safety results are
consistent with the general safety proﬁle reported in pre-
vious studies.
PEM offers several advantages for patients. This
ultrasound-guided technique requires no tumescent anes-
thesia. Patients are ambulatory immediately after the pro-
cedure. In contrast, a recovery period of as long as 7 days
has been reported with thermal ablation.19e24 Efﬁcacy can
be achieved in a single treatment. However, the recom-
mendation is to limit the amount of PEM to 15 mL per
session. Therefore, patients with more extensive disease
might need more than one treatment.CONCLUSION
PEM is a safe, effective, and convenient therapy for the
treatment of symptoms and appearance of varicose veins
of the GSV system in patients with superﬁcial venous
incompetence. This study conﬁrmed the results of
792 J.T. King et al.VANISH-2, which compared PEM doses of 0.5% and 1% to
placebo. PEM 0.5%, 1%, and 2% have an acceptable risk-
beneﬁt ratio. Treatment with PEM 1% and 2% resulted
in similar side effects, were equally effective in improving
symptoms and appearance, and had a similar duplex
response rate.
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